+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Implications of current therapeutic restrictions for primaquine and tafenoquine in the radical cure of vivax malaria



Implications of current therapeutic restrictions for primaquine and tafenoquine in the radical cure of vivax malaria



Plos Neglected Tropical Diseases 12(4): E0006440



The 8-aminoquinoline antimalarials, the only drugs which prevent relapse of vivax and ovale malaria (radical cure), cause dose-dependent oxidant haemolysis in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Patients with <30% and <70% of normal G6PD activity are not given standard regimens of primaquine and tafenoquine, respectively. Both drugs are currently considered contraindicated in pregnant and lactating women. Quantitative G6PD enzyme activity data from 5198 individuals were used to estimate the proportions of heterozygous females who would be ineligible for treatment at the 30% and 70% activity thresholds, and the relationship with the severity of the deficiency. This was used to construct a simple model relating allele frequency in males to the potential population coverage of tafenoquine and primaquine under current prescribing restrictions. Independent of G6PD deficiency, the current pregnancy and lactation restrictions will exclude ~13% of females from radical cure treatment. This could be reduced to ~4% if 8-aminoquinolines can be prescribed to women breast-feeding infants older than 1 month. At a 30% activity threshold, approximately 8-19% of G6PD heterozygous women are ineligible for primaquine treatment; at a 70% threshold, 50-70% of heterozygous women and approximately 5% of G6PD wild type individuals are ineligible for tafenoquine treatment. Thus, overall in areas where the G6PDd allele frequency is >10% more than 15% of men and more than 25% of women would be unable to receive tafenoquine. In vivax malaria infected patients these proportions will be lowered by any protective effect against P. vivax conferred by G6PD deficiency. If tafenoquine is deployed for radical cure, primaquine will still be needed to obtain high population coverage. Better radical cure antimalarial regimens are needed.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 065226525

Download citation: RISBibTeXText

PMID: 29677199

DOI: 10.1371/journal.pntd.0006440


Related references

Comparative ophthalmic assessment of patients receiving tafenoquine or chloroquine/primaquine in a randomized clinical trial for Plasmodium vivax malaria radical cure. International Ophthalmology 39(8): 1767-1782, 2019

Therapeutic Assessment of Primaquine for Radical Cure of Plasmodium vivax Malaria at Primary and Tertiary Care Centres in Southwestern India. Korean Journal of Parasitology 54(6): 733-742, 2016

Tafenoquine receives regulatory approval in USA for prophylaxis of malaria and radical cure of Plasmodium vivax. Journal of Travel Medicine 25(1):, 2018

Primaquine; a new drug for the radical cure of relapsing vivax malaria. Journal of the Medical Association of Georgia 41(4): 126, 1952

Radical cure of Chesson strain vivax malaria in man by 7, not 14, days of treatment with primaquine. American Journal of Tropical Medicine and Hygiene 26(3): 562-563, 1977

Therapeutic failure of primaquine and need for new medicines in radical cure of Plasmodium vivax. Acta Tropica 160: 35-38, 2016

A comparison of two short-course primaquine regimens for the treatment and radical cure of Plasmodium vivax malaria in Thailand. American Journal of Tropical Medicine and Hygiene 82(4): 542-547, 2010

Short report: a consideration of primaquine dose adjustment for radical cure of Plasmodium vivax malaria. American Journal of Tropical Medicine and Hygiene 62(3): 393-395, 2000

Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria. New England Journal of Medicine 380(3): 229-241, 2019

A pilot randomized controlled trial to compare the effectiveness of two 14-day primaquine regimens for the radical cure of vivax malaria in South India. Malaria Journal 17(1): 321, 2018

Status of primaquine. 2. Cure of Korean vivax malaria with primaquine and pamaquine. Jour Amer Med Assoc 149(17): 1562-1563, 1952

Compliance with 14-day primaquine therapy for radical cure of vivax malaria - a randomized placebo-controlled trial comparing unsupervised with supervised treatment. Transactions of the Royal Society of Tropical Medicine and Hygiene 98(3): 168-173, 2004

Improving the radical cure of vivax malaria (IMPROV): a study protocol for a multicentre randomised, placebo-controlled comparison of short and long course primaquine regimens. Bmc Infectious Diseases 15: 558-558, 2016

Primaquine for radical cure of Plasmodium vivax and Plasmodium ovale malaria: an observational survey (2008-2010). Journal of Travel Medicine 20(2): 134-136, 2013

The efficacy and tolerability of three different regimens of tafenoquine versus primaquine for post-exposure prophylaxis of Plasmodium vivax malaria in the Southwest Pacific. Transactions of the Royal Society of Tropical Medicine and Hygiene 102(11): 1095-1101, 2008